TSO3 announced the appointment of Dr. Bradley J. Catalone as the company’s new chief science officer.
TSO3 (TSX:TOS) announced the appointment of Dr. Bradley J. Catalone as the company’s new chief science officer.
As quoted in the press release:
Dr. Catalone has extensive knowledge of medical devices and the sterilization industry, having held significant roles within Olympus Corporation of the Americas Inc., including as Infection Control Manager, Director of Research, as well as Director of Clinical Affairs. Most recently, Dr. Catalone held the position of Vice President of Laboratory Services at Alcami Corporation with responsibility for drug development and analytical testing services. Dr. Catalone holds a Ph.D. in Microbiology and Immunology from Penn State College of Medicine, Hershey, PA and an MBA. in Business Administration from the Pennsylvania State University.
“I am very pleased to welcome Brad to the TSO3 organization” stated R.M. (Ric) Rumble TSO3‘s President and CEO. “Brad brings fifteen years of professional experience with increased accountability and responsibility within our industry. He is a strong advocate for patient safety and has directly championed improvements in device reprocessing.”